{"url_path":"/sec/nnvc/8-k/2026-07-17/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-17","source_url":"https://www.sec.gov/Archives/edgar/data/1379006/0001104659-26-084668-index.html","accession_number":"0001104659-26-084668","cik":"0001379006","ticker":"NNVC","issuer_name":"NANOVIRICIDES, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1379006/0001104659-26-084668-index.html","primary_entity_key":"0001379006","primary_entity_name":"NANOVIRICIDES, INC."},"word_count":118,"has_tables":true,"body_markdown":"**Item 9.01 Financial Statements and Exhibits.**\n\n \n\n(d) Exhibits.\n\n \n\n**Exhibit No.**\n \n**Description**\n\n[1.1](tm2620770d1_ex1-1.htm)\n \n[At Market Issuance Sales Agreement, dated as of July 17, 2026, between NanoViricides, Inc. and D. Boral Capital LLC](tm2620770d1_ex1-1.htm)\n\n[5.1](tm2620770d1_ex5-1.htm)\n \n[Opinion of Lucosky Brookman LLP](tm2620770d1_ex5-1.htm)\n\n[23.1](tm2620770d1_ex5-1.htm)\n \n[Consent of Lucosky Brookman LLP (included in Exhibit 5.1)](tm2620770d1_ex5-1.htm)\n\n104\n \nCover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements\nof the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned\nhereunto duly authorized.\n\n \n\n \n**NANOVIRICIDES, INC.**\n\n \n \n \n\nDate: July 17, 2026\nBy:\n*/s/ Anil Diwan*\n\n \nName:\nAnil Diwan\n\n \nTitle:\nPresident and Chief Executive Officer"}